Company profile
Sigyn Therapeutics, Inc.
OTC: SIGY · Healthcare · Biotechnology
#1023 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
——FH —DQ 15GM —SS 19
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), 3-yr revenue growth · ↓ Piotroski F, return on assets
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$3.3M
Employees
4
as of 2026-08-28
Market cap
$49.8k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$143.3k$143.3k2019
Net income-$3.3M-$3.3M2024
Operating income-$2.5M-$2.5M2024
Total assets$213.7k$213.7k2024
Liabilities$4.7M$4.7M2024
Equity-$4.5M-$4.5M2024
Revenue trend
FY2015 – FY2019 · USD
FY15
FY15
FY18
FY18
FY19
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Sigyn Therapeutics, Inc.’s revenue?
Sigyn Therapeutics, Inc. booked $143.3k in FY2019 revenue, growing 406% year over year — faster than 93% of Healthcare companies we track, at a -2330.6% net margin.
Peers · Healthcare
Cannabis Strategic Ventures——Anthera Pharmaceuticals, Inc.——VivoSim Labs, Inc.——Endonovo Therapeutics, Inc.——Serina Therapeutics, Inc.41DVentriPoint Diagnostics Ltd.31DNeighbors
San Diego →Key facts
CEOJames A. Joyce
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeOTC: SIGY
Employees4
IPO date2021-01-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.